Evidence map›Paper›PMID 21106907›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2011

The prototypical ranitidine analog JWS-USC-75-IX improves information processing and cognitive function in animal models.

Alvin V Terry, Jerry J Buccafusco, Elizabeth J Herman, Patrick M Callahan, Wayne D Beck, Samantha Warner, Leah Vandenhuerk, Kristy Bouchard, Gary M Schwarz, Jie Gao and 1 more

Abstract readComparative Study
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. CNTRICS final animal model task selection: control of attention.Neuroscience and biobehavioral reviews · 2013
    Review
  4. Article
  5. Review
  6. Alzheimer's disease and age-related memory decline (preclinical).Pharmacology, biochemistry, and behavior · 2011
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Alvin V TerryDepartment of Pharmacology and Toxicolog, Medical College of Georgia, Augusta, Georgia, USA. aterry@mcg.edu
Jerry J Buccafusco
Elizabeth J Herman
Patrick M Callahan
Wayne D Beck
Samantha Warner
Leah Vandenhuerk
Kristy Bouchard
Gary M Schwarz
Jie Gao
James M Chapman
Augusta University · USUniversity of South Carolina · USInstitute of Pharmacology · CZ

Funding

Procognitive and Antipsychotic Actions of JWS-USC-75-IXR21AG032140 · NIA · AUGUSTA UNIVERSITY · PI TERRY, ALVIN V · 2008 to 2009
$351k
NIA NIH HHS R21 AG032140
6 · The paper itself

Abstract

This study was designed to evaluate further a prototypical ranitidine analog, JWS-USC-75-IX, [(3-[[[2-[[(5-dimethylaminomethyl)-2-furanyl]methyl]thio]ethyl]amino]-4-nitropyridazine, JWS], for neuropharmacologic properties that would theoretically be useful for treating cognitive and noncognitive behavioral symptoms of neuropsychiatric disorders. JWS was previously found to inhibit acetylcholinesterase (AChE) activity, serve as a potent ligand at muscarinic M₂ acetylcholine receptors, and elicit positive effects on spatial learning, passive avoidance, and working memory in rodents. In the current study, JWS was evaluated for binding activity at more than 60 neurotransmitter receptors, transporters, and ion channels, as well as for inhibitory activity at AChE and butyrylcholinesterase (BChE). The results indicate that JWS inhibits AChE and BChE at low (micromolar) concentrations and that it is a functional antagonist at M₂ receptors (K(B) = 320 nM). JWS was subsequently evaluated orally across additional behavioral assays in rodents (dose range, 0.03-10.0 mg/kg) as well as nonhuman primates (dose range, 0.05-2.0 mg/kg). In rats, JWS improved prepulse inhibition (PPI) of the acoustic startle response in nonimpaired rats and attenuated PPI deficits in three pharmacologic impairment models. JWS also attenuated scopolamine and (-)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate (MK-801)-related impairments in a spontaneous novel object recognition task and a five-choice serial reaction time task, respectively. In monkeys, JWS elicited dose-dependent improvements of a delayed match-to-sample task as well as an attention-related version of the task where randomly presented (task-relevant) distractors were presented. Thus, JWS (potentially via effects at several drug targets) improves information processing, attention, and memory in animal models and could potentially treat the cognitive and behavioral symptoms of some neuropsychiatric illnesses.

Indexed as

Models, AnimalAnimalsAvoidance LearningCognitionFemaleMacaca nemestrinaMaleMemory, Short-TermMotor ActivityRanitidineRatsRats, WistarReaction TimeRanitidine

Identifiers

PMID21106907
PMCPMC3061527
OpenAlexW2140688659

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.